| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2083156 | Drug Discovery Today: Therapeutic Strategies | 2006 | 7 Pages |
Abstract
This paper briefly reviews what human γδ T lymphocytes are and what they can do in anticancer and anti-infectious immunity. Both phosphoantigens, a new class of immunostimulatory leads, and some anticancer aminobisphosphonates selectively activate these lymphocytes. So, new molecules under development and endowed with diverse additional bioactivities are promising new leads for the design of highly innovative anticancer immunotherapies.
Section editors:Claudine Bruck – GlaxoSmithKline, King of Prussia, USAMichel Goldman – University of Brussels, Brussels, Belgium
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Christian Belmant, Donatella Decise, Jean-Jacques Fournié,